Evidence mapPaperPMID 39639199Full record

Observational studyBMC nephrology2024

A retrospective multi-site examination of chronic kidney disease using longitudinal laboratory results and metadata to identify clinical and financial risk.

Mark Fung, Aya Haghamad, Elizabeth Montgomery, Kathleen Swanson, Myra L Wilkerson, Kimon Stathakos, Richard VanNess, Sarah A Nowak, Clayton Wilburn, Haluk Kavus and 10 more

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in BMC nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mark Fung *Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT, USA.
Aya Haghamad *Department of Pathology and Laboratory Medicine, Northwell Health, New Hyde Park, NY, USA.
Elizabeth MontgomeryNational Kidney Foundation, New York, NY, USA.
Kathleen SwansonProject Santa Fe Foundation, Salt Lake City, UT, USA.
Myra L WilkersonDepartment of Pathology and Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA.
Kimon StathakosDepartment of Pathology and Laboratory Medicine, Northwell Health, New Hyde Park, NY, USA.
Richard VanNessTriCore Reference Laboratories, Albuquerque, NM, USA.
Sarah A NowakDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT, USA.
Clayton WilburnDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT, USA.
Haluk KavusDepartment of Pathology and Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA.
Mohammed Amer SwidDepartment of Pathology and Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA.
Nkemakonam OkoyeDepartment of Pathology and Laboratory Medicine, Northwell Health, New Hyde Park, NY, USA.
Yonah C ZiembaDepartment of Pathology and Laboratory Medicine, Northwell Health, New Hyde Park, NY, USA.
Girish RamrattanDepartment of Pathology and Laboratory Medicine, Northwell Health, New Hyde Park, NY, USA.
Jonathan MacyDepartment of Pathology and Laboratory Medicine, Northwell Health, New Hyde Park, NY, USA.
John McConnellDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT, USA.
Mary Jane LewisNational Kidney Foundation, New York, NY, USA.
Beth BaileyProject Santa Fe Foundation, Salt Lake City, UT, USA.
Khosrow ShotorbaniProject Santa Fe Foundation, Salt Lake City, UT, USA.
James M CrawfordDepartment of Pathology and Laboratory Medicine, Northwell Health, New Hyde Park, NY, USA. jcrawford1@northwell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA retrospective observational study was conducted at 3 health care organizations to identify clinical gaps in care for patients with stage 3 or 4 chronic kidney disease (CKD), and financial opportunity from U.S. risk adjustment payment systems. Lack of evaluation for CKD in patients with diabetes was also assessed.

methodsOutpatient longitudinal laboratory results and patient metadata available in the electronic medical record, laboratory information system, and/or laboratory billing or facility claims data for the calendar year 2021 were evaluated. Laboratory results were compared to billing data (ICD-10 codes) and risk adjustment scores including Hierarchical Condition Categories (HCC) to determine if laboratory-identified CKD was coded as a disease condition in the electronic medical record. Adults 18 to 75 years of age were included; inpatient laboratory results and pregnant individuals were excluded.

resultsAt the 3 institutions, 12,478 of 16,063 (78%), 487 of 1511 (32%) and 19,433 of 29,277 (66%) of patients with laboratory evidence of stage 3 or 4 CKD did not have a corresponding ICD-10 or HCC code for CKD in the electronic medical record. For patients at the 3 institutions with diabetes on the basis of an HbA1c value of ≥ 6.5%, 34,384 of 58,278 (59%), 2274 of 2740 (83%) and 40,378 of 52,440 (77%) had not undergone guideline-recommended laboratory testing for CKD during the same 12 months. Using publicly available data for calendar year 2021, an estimated 3246 of 32,398 patients (9.9%) at the 3 institutions with undocumented CKD stages 3-4 would be enrolled in Medicare Advantage or Affordable Care Act Marketplace programs. The imputed lost reimbursement under risk-adjusted payment systems for under-documentation of CKD in this subset of patients was $2.85 M for the three institutions combined, representing lost opportunity for both identification and proactive clinical management of these patients, and financial recovery for the costs of providing that care.

conclusionsClinical laboratories can provide value beyond routine diagnostics, helping to close gaps in care for identification and management of CKD, stratifying subgroups of patients to identify risk, and capturing missed reimbursement through risk adjustment factors.

Indexed as

Electronic Health RecordsRenal Insufficiency, ChronicAdolescentAdultAgedFemaleHumansLongitudinal StudiesMaleMetadataMiddle AgedRetrospective StudiesRisk AdjustmentUnited StatesYoung AdultClinical lab 2.0Clinical laboratoryDiabetesHeart failurePopulation healthProject Santa FeRisk adjustment

Identifiers

PMID39639199
PMCPMC11622455

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.